SeaStar Medical Announces Appointment of Michael Messinger as CFO

Core Insights - SeaStar Medical Holding Corporation has appointed Michael Messinger as Chief Financial Officer, bringing over 25 years of healthcare industry experience to the company [1][2] Company Overview - SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure [4] - The company's first commercial product, QUELIMMUNE (SCD-PED) therapy, is FDA approved for life-threatening acute kidney injury (AKI) in critically ill pediatric patients [4] - The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation for six therapeutic indications by the FDA, facilitating a faster approval process and better reimbursement dynamics [4] Leadership and Experience - Michael Messinger has extensive experience in financing and accounting for drug discovery and development organizations, previously serving as CFO of ContraFect Corporation [2] - He has successfully led companies through significant financial milestones, including a Nasdaq IPO and securing a $90 million contract with BARDA [2] Product and Market Potential - The QUELIMMUNE therapy has shown remarkable commercial results in pediatric AKI patients and aims to expand to address multiple indications [3] - SeaStar Medical is conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a condition affecting over 200,000 adults in the U.S. annually [4]